Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells
PDF | HTML | How to cite
Metrics: PDF 1589 views | HTML 2717 views | ?
Wei-Chien Huang1,2,3,4, Chao-Ming Hung5,6, Ching-Ting Wei5,6,*, Tsung-Ming Chen7,*, Pei-Hsuan Chien8, Hsiao-Lin Pan5, Yueh-Ming Lin9, Yun-Ju Chen5,8,10
1The Ph.D. program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung 404, Taiwan
2Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan
3Center for Molecular Medicine, China Medical University and Hospital, Taichung 404, Taiwan
4Department of Biotechnology, Asia University, Taichung 413, Taiwan
5School of Medicine for International Students, I-Shou University, Kaohsiung 824, Taiwan
6Department of General Surgery, E-Da Hospital, Kaohsiung 824, Taiwan
7Department and Graduate Institute of Aquaculture, National Kaohsiung Marine University, Kaohsiung 811, Taiwan
8Department of Medical Research, E-Da Hospital, Kaohsiung 824, Taiwan
9Division of Colorectal Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
10Department of Biological Science & Technology, I-Shou University, Kaohsiung 824, Taiwan
*These authors have contributed equally to this work
Yun-Ju Chen, email: [email protected]
Keywords: lapatinib, interleukin-6, HER2, resistance, breast cancer
Received: February 10, 2016 Accepted: August 09, 2016 Published: August 22, 2016
Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers. Clinically, lapatinib has shown promising benefits for HER2-positive breast cancer patients; however, patients eventually acquire resistance, limiting its long-term use. In a previous study, we found that interleukin-6 (IL-6) production was increased in acquired lapatinib-resistant HER2-positive breast cancer cells. In the present study, we confirmed that lapatinib-resistant cells had elevated IL-6 expression and also maintained both stemness population and property. The increase in IL-6 was required for stemness property maintenance, which was mediated primarily through the activation of signal transducer and activator of transcription 3 (STAT3). Blocking IL-6 activity reduced spheroid formation, cell viability and subsequently overcame lapatinib resistance, whereas stimulation of IL-6 rendered parental cells more resistant to lapatinib-induced cytotoxicity. These results point to a novel mechanism underlying lapatinib resistance and provide a potential strategy to overcome resistance via IL-6 inhibition.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.